LOS ANGELES, July 21, 2017 -- Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Pingtan Marine Enterprise Ltd. (“Pingtan” or the “Company”) (Nasdaq:PME) for possible violations of federal securities laws between August 8, 2016 and May 10, 2017, inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm prior to the August 22, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may choose to do nothing and be an absent class member as well.
According to the Complaint, during the Class Period, Pingtan made false and/or misleading statements and/or failed to disclose: that the Company is banned from Indonesia; that Pingtan used investor capital to finance illegal activity, including forced labor, illegal fishing, and human trafficking; and that as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. When this information was released, shares of Pingtan fell in value materially, which caused investors harm according to the Complaint.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/


Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 



